Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 9Phase 1/2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 7OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Plasma cell 1

Conditions

Glioblastoma 2Brain Neoplasms 2Multiple Myeloma 1Gliosarcoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × tipifarnib × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

NCT00005859 2018-06-26

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
136 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00361088 2013-11-25

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
42 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡